Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States

Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States

Item
http://www.wikidata.org/entity/Q35991480
Effects of the Share 35 Rule on Waitlist and Liver Transplantation Outcomes for Patients with Hepatocellular Carcinoma.Peroxiredoxin 6 attenuates ischemia‑ and hypoxia‑induced liver damage of brain‑dead donorsCurrent Status of Liver Allocation in the United StatesIndependent prognostic factors for posttransplant survival in hepatocellular carcinoma patients undergoing liver transplantation.Patient-reported outcomes in liver transplant recipients with hepatocellular carcinoma.Race/Ethnicity-Specific Outcomes Among Chronic Hepatitis C Virus Patients Listed for Liver Transplantation.Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States.Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease.Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.Advances and Future Directions in the Treatment of Hepatocellular CarcinomaTwenty years of Milan criteria and live-donor liver transplantation in the US: a contrast in transparency, regulation, and expectation.Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form.Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma.
P2860

Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States

Item
http://www.wikidata.org/entity/Q35991480
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Delayed hepatocellular carcino ...... ransplant in the United States
@ast
Delayed hepatocellular carcino ...... ransplant in the United States
@en
type
label
Delayed hepatocellular carcino ...... ransplant in the United States
@ast
Delayed hepatocellular carcino ...... ransplant in the United States
@en
prefLabel
Delayed hepatocellular carcino ...... ransplant in the United States
@ast
Delayed hepatocellular carcino ...... ransplant in the United States
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Delayed hepatocellular carcino ...... ransplant in the United States
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932